1
|
Durden AA, Cass GK, Newton C. Sertoli-Leydig tumor and DICER1 gene mutation: A case series and literature review. J Obstet Gynaecol Res 2024. [PMID: 38599636 DOI: 10.1111/jog.15939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Accepted: 03/23/2024] [Indexed: 04/12/2024]
Abstract
OBJECTIVE Sertoli-Leydig cell tumors (SLCTs) are rare neoplasms occurring in young women with 60% associated with DICER1 mutations. This is only the second published case series of patients with SLCTs with associated DICER1 gene alterations. DICER1 syndrome is a rare inherited tumor-susceptibility syndrome affecting organs such as the ovaries. We use this case series to inform readers on this increasingly important condition in gynecology. METHODS AND RESULTS We present three young females presenting with secondary amenorrhoea, hirsutism, acne and in one case tonic-clonic seizures. All cases had high testosterone levels and an adnexal mass on ultrasound. Following surgical removal, pathology confirmed SLCTs and genetic testing followed. All three patients had DICER1 syndrome with two patients subsequently found to be related. DISCUSSION The prevalence of DICER1 syndrome in the population is estimated to be 1 in 10 000 with a spectrum of sex cord stromal tumors affecting young women. The associated pathological classifications and management. This paper describes the DICER1 gene and the associated tumor predisposition syndrome alongside a surveillance protocol for use in clinical practice. It promotes discussion over the importance of early clinical genetics involvement in sex-cord stromal tumors and the associated difficulties in counseling in a young patient population. Genetic testing and early detection are imperative for targeted surveillance of at-risk organs to be performed but despite this there is no international guidance. The cases highlight the psychological impact of tumors in young patients and provokes an ethical discussion over DICER1 gene's inclusion in preimplantation genetics. CONCLUSIONS DICER1 syndrome is a rare but increasingly important condition in pediatric and adolescent gynecology with a paucity of published data and case reports. This makes international consensus on management and surveillance difficult.
Collapse
Affiliation(s)
- Andrew A Durden
- Department of Gynaecology Oncology, St Michael's Hospital, University Hospital Bristol and Weston NHS Trust, Bristol, England
| | - Gemma K Cass
- Department of Gynaecology Oncology, St Michael's Hospital, University Hospital Bristol and Weston NHS Trust, Bristol, England
| | - Claire Newton
- Department of Gynaecology Oncology, St Michael's Hospital, University Hospital Bristol and Weston NHS Trust, Bristol, England
- University of Bristol, Bristol, England
| |
Collapse
|
2
|
Akkus S, Elkhooly M, Amatya S, Shrestha K, Sharma K, Kagzi Y, Khan E, Gupta R, Piquet AL, Jaiswal S, Wen S, Tapia M, Samant R, Sista SR, Sriwastava S. Autoimmune and paraneoplastic neurological disorders: A review of relevant neuroimaging findings. J Neurol Sci 2023; 454:120830. [PMID: 37856996 DOI: 10.1016/j.jns.2023.120830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 09/28/2023] [Accepted: 10/04/2023] [Indexed: 10/21/2023]
Abstract
INTRODUCTION Paraneoplastic neurologic syndromes (PNS) and autoimmune encephalitis (AIE) are immune-mediated disorders. PNS is linked to cancer, while AIE may not Their clinical manifestations and imaging patterns need further elucidation. OBJECTIVE/AIMS To investigate the clinical profiles, antibody associations, neuroimaging patterns, treatments, and outcomes of PNS and AIE. METHODS A systematic review of 379 articles published between 2014 and 2023 was conducted. Of the 55 studies screened, 333 patients were diagnosed with either PNS or AIE and tested positive for novel antibodies. Data on demographics, symptoms, imaging, antibodies, cancer associations, treatment, and outcomes were extracted. RESULTS The study included 333 patients (mean age 54 years, 67% males) with PNS and AIE positive for various novel antibodies. 84% had central nervous system issues like cognitive impairment (53%), rhombencephalitis (17%), and cerebellar disorders (24%). Neuroimaging revealed distinct patterns with high-risk antibodies associated with brainstem lesions in 98%, cerebellar in 91%, hippocampal in 98%, basal ganglia in 75%, and spinal cord in 91%, while low/intermediate-risk antibodies were associated with medial temporal lobe lesions in 71% and other cortical/subcortical lesions in 55%. High-risk antibodies were associated with younger males, deep brain lesions, and increased mortality of 61%, while low/intermediate-risk antibodies were associated with females, cortical/subcortical lesions, and better outcomes with 39% mortality. Associated cancers included seminomas (23%), lung (19%), ovarian (2%), and breast (2%). Treatments included IVIG, chemotherapy, and plasmapheresis. Overall mortality was 25% in this cohort. CONCLUSION PNS and AIE have distinct clinical and radiological patterns based on antibody profiles. High-risk antibodies are associated with increased mortality while low/intermediate-risk antibodies are associated with improved outcomes. Appropriate imaging and antibody testing are critical for accurate diagnosis.
Collapse
Affiliation(s)
- Sema Akkus
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Mahmoud Elkhooly
- Department of Neurology, Wayne state University, Detroit, MI, USA; Department of Neurology, Southern Illinois university, Springfield, IL, USA; Department of Neuropsychiatry, Minia University, Egypt
| | - Suban Amatya
- Department of Medicine, Patan Academy of Health Sciences, Kathmandu, Nepal
| | - Kriti Shrestha
- Department of Medicine, Patan Academy of Health Sciences, Kathmandu, Nepal
| | - Kanika Sharma
- Division of Multiple Sclerosis and Neuroimmunology Department of Neurology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX,USA
| | - Yusuf Kagzi
- Mahatma Gandhi Memorial Medical College, Indore, India
| | - Erum Khan
- Department of Neurology, University of Alabama at Birmingham, Al, USA
| | - Rajesh Gupta
- Division of Multiple Sclerosis and Neuroimmunology Department of Neurology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX,USA
| | - Amanda L Piquet
- Neuroimmunology, Neuroinfectious Disease and Neurohospitalist Sections, University of Colorado School of Medicine, CO, USA
| | - Shruti Jaiswal
- Department of Neuro-oncology, MD Anderson Cancer Center, Houston, TX, USA
| | - Sijin Wen
- West Virginia Clinical Transitional Science, Morgantown, WV, USA
| | - Michaela Tapia
- West Virginia Clinical Transitional Science, Morgantown, WV, USA
| | - Rohan Samant
- Department of Neuroradiology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Sri Raghav Sista
- Division of Multiple Sclerosis and Neuroimmunology Department of Neurology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX,USA
| | - Shitiz Sriwastava
- Division of Multiple Sclerosis and Neuroimmunology Department of Neurology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX,USA.
| |
Collapse
|
3
|
Serrano-Castro PJ, Rodríguez-Uranga JJ, Cabezudo-García P, García-Martín G, Romero-Godoy J, Estivill-Torrús G, Ciano-Petersen NL, Oliver B, Ortega-Pinazo J, López-Moreno Y, Aguilar-Castillo MJ, Gutierrez-Cardo AL, Ramírez-García T, Sanchez-Godoy L, Carreño M. Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. NEUROLOGY(R) NEUROIMMUNOLOGY & NEUROINFLAMMATION 2023; 10:e200151. [PMID: 37607753 PMCID: PMC10443460 DOI: 10.1212/nxi.0000000000200151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 06/09/2023] [Indexed: 08/24/2023]
Abstract
BACKGROUND AND OBJECTIVES Autoimmune-associated epilepsy (AAE) with antiglutamic acid decarboxylase 65 (GAD65) antibodies is considered a T-cell-mediated encephalitis that evolves to drug-resistant epilepsy. We do not have an effective therapeutic strategy for these patients. Because the GAD enzyme is primarily responsible for the conversion of glutamate to GABA, the mechanism of epileptogenesis in this condition predicts decreased levels of GABA content in synaptic vesicles. Cenobamate (CNB) acts as a positive allosteric modulator at synaptic and extra synaptic GABAA receptors, producing increased inhibitory neurotransmission in the brain. This mechanism could be especially beneficial in AAE with anti-GAD65 antibodies because it would be able to correct the imbalance due to the GABAergic stimulation deficit in postsynaptic neurons. METHODS We recruit a retrospective multicentric consecutive case series of AAE with anti-GAD65 antibodies from 5 epilepsy units in Spain who have received treatment with CNB. RESULTS A total of 8 patients were recruited. This cohort of highly refractory patients have failed a mean of 9.50 (SD = 3.20) ASM without control of seizures for sustained periods of time. The average number of seizures per month during the previous 3 months before CNB treatment was 19.63 (SD = 17.03). After the introduction of CNB improvement was achieved in all our patients, with a median reduction in the number of seizures of 92.22% (interquartile range [IQR]: 57.25-98.75). The mean follow-up was 156.75 days (SD = 68.23). In patients with concomitant treatment with clobazam (CLB), the median percentage of seizure reduction was higher than those not taking CLB: 94.72% (IQR: 87.25-100) vs 41.50% (p = 0.044) and also higher than the control group of patients with refractory epilepsy not related to anti-GAD65 treated with the same combination: 94.72% (IQR: 87.25-100) vs 45.00% (IQR: 25.00-87.00) (p = 0.019). DISCUSSION Treatment with the combination CNB + CLB could be a type of personalized medicine in patients with AAE with anti-GAD65. Our preliminary data will need to be endorsed with new prospective and controlled studies.
Collapse
Affiliation(s)
- Pedro J Serrano-Castro
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain.
| | - Juan J Rodríguez-Uranga
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Pablo Cabezudo-García
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain.
| | - Guillermina García-Martín
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Jorge Romero-Godoy
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Guillermo Estivill-Torrús
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Nicolás Lundahl Ciano-Petersen
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Begoña Oliver
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Jesús Ortega-Pinazo
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Yolanda López-Moreno
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Maria J Aguilar-Castillo
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Antonio L Gutierrez-Cardo
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Teresa Ramírez-García
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Lorenzo Sanchez-Godoy
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| | - Mar Carreño
- From the Epilepsy Unit, Regional University Hospital of Málaga (P.J.S.-C., P.C.-G., G.G.-M., Y.L.-M); Institute for Biomedical Research of Málaga (IBIMA-Plataforma Bionand), Málaga (P.J.S.-C., P.C.-G., G.G.-M., N.L.C.-P., B.O., G.E.-T., J.O.-P., T.R.-G., L.S.-G.); Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA), Spain (P.J.S.-C., J.J.R.-U., P.C.-G., G.G.-M., B.O.) University of Málaga (P.J.S.-C., B.O.); Vithas Hospital of Málaga, Spain (P.J.S.-C., P.C.-G.); Epilepsy Unit, Center for Avanced Neurology of Seville (J.J.R.-U.); Epilepsy Unit, Virgen de la Victoria University Hospital of Málaga (J.R.-G.), Biotechnology Unit, Regional University Hospital of Málaga (M.J.A.-C., L.S.-G.); Nuclear Medicina Unit, Regional University Hospital of Málaga (A.L.G.-C.); Epilepsy Unit, Clinic Hospital of Barcelona (M.C.), August Pi i Sunyer Biomedical Research Institute, Barcelona (M.C.), European Reference Network for Rare and Complex Epilepsies (EPICARE) (M.C.), Spain
| |
Collapse
|
4
|
Rada A, Bien CG. What is autoimmune encephalitis-associated epilepsy? Proposal of a practical definition. Epilepsia 2023; 64:2249-2255. [PMID: 37353891 DOI: 10.1111/epi.17699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 06/21/2023] [Accepted: 06/21/2023] [Indexed: 06/25/2023]
Abstract
Seizures resulting from cerebral autoimmunity are either acutely symptomatic in the context of autoimmune encephalitis (AIE) with neural surface antibodies, or they are indicative of an enduring predisposition to seizures, that is, epilepsy. Here, we propose a practical definition for autoimmune encephalitis-associated epilepsy (AEAE): Seizures associated with antibodies against glutamic acid decarboxylase, paraneoplastic syndromes, or Rasmussen encephalitis are classified as AEAE. AEAE secondary to AIE with antibodies against the N-methyl-D-aspartate receptor, leucine-rich glioma inactivated protein 1, contactin-associated protein-2, or γ-aminobutyric acid-B receptor can be diagnosed if the following criteria are met: seizures persist for at least 2 years after immunotherapy initiation; no signs of encephalitis on magnetic resonance imaging and no fluorodeoxyglucose positron emission tomography hypermetabolism; normal cerebrospinal fluid cell count; and a substantial decrease in antibody titers. This classification corresponds to different disease mechanisms. While AIE results from the pathogenic effects of neural antibodies, AEAE is probably the consequence of encephalitis-related tissue damage and thereby mainly structurally mediated. The distinction between AIE and AEAE also has practical consequences: In AIE, immunotherapy is usually highly beneficial, whereas anti-seizure medication has little effect. In AEAE, immunotherapy is less promising and the usual anti-seizure interventions are preferable. In addition, the diagnosis of AEAE has social consequences in terms of driving and professional limitations.
Collapse
Affiliation(s)
- Anna Rada
- Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany
| | - Christian G Bien
- Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany
| |
Collapse
|
5
|
Antaya TC, Le BN, Richard L, Qureshi A, Shariff SZ, Sposato LA, Burneo JG. Epilepsy Surgery in Adult Stroke Survivors with New-Onset Drug-Resistant Epilepsy. Can J Neurol Sci 2023; 50:673-678. [PMID: 36373342 DOI: 10.1017/cjn.2022.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Despite its effectiveness, surgery for drug-resistant epilepsy is underutilized. However, whether epilepsy surgery is also underutilized among patients with stroke-related drug-resistant epilepsy is unclear. Therefore, our objectives were to estimate the rates of epilepsy surgery assessment and receipt among patients with stroke-related drug-resistant epilepsy and to identify factors associated with these outcomes. METHODS We used linked health administrative databases to conduct a population-based retrospective cohort study of adult Ontario, Canada residents discharged from an Ontario acute care institution following the treatment of a stroke between January 1, 1997, and December 31, 2020, without prior evidence of seizures. We excluded patients who did not subsequently develop drug-resistant epilepsy and those with other epilepsy risk factors. We estimated the rates of epilepsy surgery assessment and receipt by March 31, 2021. We planned to use Fine-Gray subdistribution hazard models to identify covariates independently associated with our outcomes, controlling for the competing risk of death. RESULTS We identified 265,081 patients who survived until discharge following inpatient stroke treatment, 1,902 (0.7%) of whom subsequently developed drug-resistant epilepsy (805 women; mean age: 67.0 ± 13.1 years). Fewer than six (≤0.3%) of these patients were assessed for or received epilepsy surgery before the end of follow-up (≤55.5 per 100,000 person-years). Given that few outcomes were identified, we could not proceed with the multivariable analyses. CONCLUSIONS Patients with stroke-related drug-resistant epilepsy are infrequently considered for epilepsy surgery that could reduce morbidity and mortality.
Collapse
Affiliation(s)
- Tresah C Antaya
- Neuroepidemiology Research Unit, Department of Clinical Neurological Sciences, Western University, 1151 Richmond St, London, OntarioN6A 3K7, Canada
| | - Britney N Le
- ICES Western, 800 Commissioners Rd E, London, OntarioN6A 5W9, Canada
| | - Lucie Richard
- ICES Western, 800 Commissioners Rd E, London, OntarioN6A 5W9, Canada
| | - Amna Qureshi
- Neuroepidemiology Research Unit, Department of Clinical Neurological Sciences, Western University, 1151 Richmond St, London, OntarioN6A 3K7, Canada
| | - Salimah Z Shariff
- ICES Western, 800 Commissioners Rd E, London, OntarioN6A 5W9, Canada
| | - Luciano A Sposato
- Department of Clinical Neurological Sciences, Western University, 339 Windermere Rd, London, OntarioN6A 5A5, Canada
| | - Jorge G Burneo
- Neuroepidemiology Research Unit, Department of Clinical Neurological Sciences, Western University, 1151 Richmond St, London, OntarioN6A 3K7, Canada
- ICES Western, 800 Commissioners Rd E, London, OntarioN6A 5W9, Canada
- Epilepsy Program, Department of Clinical Neurological Sciences, Western University, 339 Windermere Rd, London, OntarioN6A 5A5, Canada
| |
Collapse
|
6
|
Kim S, Kim H, Lee J, Lee SB, Hong YJ, Oh YS, Park JW. Risk of epilepsy in gonadal teratoma: a nationwide population-based study. Sci Rep 2023; 13:11206. [PMID: 37433861 DOI: 10.1038/s41598-023-38255-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 07/05/2023] [Indexed: 07/13/2023] Open
Abstract
Epilepsy is a common neurological disease. Systemic tumors are associated with an increased risk of epileptic events. Paraneoplastic encephalitis related to gonadal teratoma is frequently accompanied by seizures and life-threatening status epilepticus (SE). However, the risk of epilepsy in gonadal teratoma has not been studied. This study aims to investigate the relationship between epileptic events and gonadal teratoma. This retrospective cohort study used the Korean National Health Insurance (KNHI) database. The study population was divided into two study arms (ovarian teratoma vs. control and testicular teratoma vs. control) with 1:2 age and gender-matched control groups without a history of gonadal teratoma or other malignancy. Participants with other malignancies, neurologic disorders, and metastatic brain lesions were excluded. We observed the occurrence of epileptic events during the observation period (2013-2018) and investigated the risk of epileptic events in each gonadal teratoma group compared to controls. In addition, the influence of malignancy and tumor removal was investigated. The final analysis included 94,203 women with ovarian teratoma, 2314 men with testicular teratoma, and controls. Ovarian teratoma is associated with a higher risk of epilepsy without SE (HR, 1.244; 95% CI 1.112-1.391) and epilepsy with SE (HR, 2.012; 95% CI 1.220-3.318) compared to the control group. The risk of epilepsy without SE was higher in malignant ovarian teratoma (HR, 1.661; 95% CI 1.358-2.033) than in benign (HR, 1.172; 95% CI 1.037-1.324). Testicular teratoma did not show significant relations with epileptic events. The risk of epileptic events showed a tendency to decrease after removing the ovarian teratoma. This study found that ovarian teratoma is associated with a higher risk of epileptic events, especially in malignant tumors, whereas testicular teratoma did not show significant differences in epileptic events compared to the control group. This study adds to the current understanding of the association between gonadal teratoma and epileptic events.
Collapse
Affiliation(s)
- Seonghoon Kim
- Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Hasung Kim
- Data Science Team, Hanmi Pharm. Co., Ltd., Seoul, Republic of Korea
| | - Jungkuk Lee
- Data Science Team, Hanmi Pharm. Co., Ltd., Seoul, Republic of Korea
| | - Si Baek Lee
- Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Yun Jeong Hong
- Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Yoon-Sang Oh
- Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Jeong Wook Park
- Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
| |
Collapse
|
7
|
Gibbs-Shelton S, Benderoth J, Gaykema RP, Straub J, Okojie KA, Uweru JO, Lentferink DH, Rajbanshi B, Cowan MN, Patel B, Campos-Salazar AB, Perez-Reyes E, Eyo UB. Microglia play beneficial roles in multiple experimental seizure models. Glia 2023; 71:1699-1714. [PMID: 36951238 DOI: 10.1002/glia.24364] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 03/09/2023] [Accepted: 03/10/2023] [Indexed: 03/24/2023]
Abstract
Seizure disorders are common, affecting both the young and the old. Currently available antiseizure drugs are ineffective in a third of patients and have been developed with a focus on known neurocentric mechanisms, raising the need for investigations into alternative and complementary mechanisms that contribute to seizure generation or its containment. Neuroinflammation, broadly defined as the activation of immune cells and molecules in the central nervous system (CNS), has been proposed to facilitate seizure generation, although the specific cells involved in these processes remain inadequately understood. The role of microglia, the primary inflammation-competent cells of the brain, is debated since previous studies were conducted using approaches that were less specific to microglia or had inherent confounds. Using a selective approach to target microglia without such side effects, we show a broadly beneficial role for microglia in limiting chemoconvulsive, electrical, and hyperthermic seizures and argue for a further understanding of microglial contributions to contain seizures.
Collapse
Affiliation(s)
- Synphane Gibbs-Shelton
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Jordan Benderoth
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA
| | - Ronald P Gaykema
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Justyna Straub
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Kenneth A Okojie
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA
| | - Joseph O Uweru
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| | - Dennis H Lentferink
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA
| | - Binita Rajbanshi
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Maureen N Cowan
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| | - Brij Patel
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| | - Anthony Brayan Campos-Salazar
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| | - Edward Perez-Reyes
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Ukpong B Eyo
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, Virginia, USA
- Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| |
Collapse
|
8
|
Shelton-Gibbs S, Benderoth J, Gaykema RP, Straub J, Okojie KA, Uweru JO, Lentferink DH, Rajbanshi B, Cowan MN, Patel B, Campos-Salazar AB, Perez-Reyes E, Eyo UB. Microglia play beneficial roles in multiple experimental seizure models. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.03.04.531090. [PMID: 36945556 PMCID: PMC10028974 DOI: 10.1101/2023.03.04.531090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
Abstract
Seizure disorders are common, affecting both the young and the old. Currently available antiseizure drugs are ineffective in a third of patients and have been developed with a focus on known neurocentric mechanisms, raising the need for investigations into alternative and complementary mechanisms that contribute to seizure generation or its containment. Neuroinflammation, broadly defined as the activation of immune cells and molecules in the central nervous system (CNS), has been proposed to facilitate seizure generation, although the specific cells involved in these processes remain inadequately understood. The role of microglia, the primary inflammation-competent cells of the brain, is debated since previous studies were conducted using approaches that were less specific to microglia or had inherent confounds. Using a selective approach to target microglia without such side effects, we show a broadly beneficial role for microglia in limiting chemoconvulsive, electrical, and hyperthermic seizures and argue for a further understanding of microglial contributions to contain seizures.
Collapse
Affiliation(s)
- Synphane Shelton-Gibbs
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Jordan Benderoth
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
| | - Ronald P. Gaykema
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Justyna Straub
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Kenneth A. Okojie
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
| | - Joseph O. Uweru
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| | - Dennis H. Lentferink
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
| | - Binita Rajbanshi
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Maureen N. Cowan
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| | - Brij Patel
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
| | - Anthony Brayan Campos-Salazar
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
| | - Edward Perez-Reyes
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA
| | - Ukpong B. Eyo
- Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA
- Department of Neuroscience, University of Virginia, Charlottesville, VA, USA
- Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA
| |
Collapse
|
9
|
Dziadkowiak E, Moreira H, Buska-Mach K, Szmyrka M, Budrewicz S, Barg E, Janik M, Pokryszko-Dragan A. Occult Autoimmune Background for Epilepsy-The Preliminary Study on Antibodies Against Neuronal Surface Antigens. Front Neurol 2021; 12:660126. [PMID: 34744955 PMCID: PMC8567837 DOI: 10.3389/fneur.2021.660126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 09/20/2021] [Indexed: 11/13/2022] Open
Abstract
Objective: The objective of the study was to determine the incidence of antibodies against neuronal surface antigens (NSA-ab) in patients with different types of epilepsy, in comparison with the subjects diagnosed with immune-mediated disorders. Methods: Forty patients with drug-resistant epilepsy (DRE) of unknown origin, 16 with post-stroke epilepsy, and 23 with systemic autoimmune disorders (SAD) with CNS involvement were included. NSA-ab were sought in serum using indirect immunofluorescence method. Relationships were analyzed between presence of NSA-ab and clinical presentation. Results: NSA-ab was detected in the sera from five patients: anti-DPPX in one patient, anti-AMPAR1/R2 in two, anti-LGI1 in one and, in one case, both anti-CASPR2 and DPPX IgG. Out of these five patients, three represented the SAD subgroup and two the DRE subgroup. None of the patients with post-stroke epilepsy was positive for NSA-ab. Significance: Autoimmune etiology is worth considering in patients with drug-resistant epilepsy of unknown origin. The presence of NSA-ab in patients with systemic autoimmune disorders may be caused by unspecifically enhanced autoimmune reactivity. NSA-ab seem not to be related to epilepsy resulting from ischemic brain injury.
Collapse
Affiliation(s)
- Edyta Dziadkowiak
- Department of Neurology, Wroclaw Medical University, Wroclaw, Poland
| | - Helena Moreira
- Department of Basic Medical Sciences, Wroclaw Medical University, Wroclaw, Poland
| | | | - Magdalena Szmyrka
- Department of Rheumatology, Wroclaw Medical University, Wroclaw, Poland
| | | | - Ewa Barg
- Department of Basic Medical Sciences, Wroclaw Medical University, Wroclaw, Poland
| | | | | |
Collapse
|
10
|
Chen SS, Zhang YF, Di Q, Shi JP, Wang LL, Lin XJ, Yu N. Predictors and prognoses of epilepsy after anti-neuronal antibody-positive autoimmune encephalitis. Seizure 2021; 92:189-194. [PMID: 34551365 DOI: 10.1016/j.seizure.2021.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 09/09/2021] [Accepted: 09/12/2021] [Indexed: 10/20/2022] Open
Abstract
PURPOSE This study aimed to investigate the incidence and predictors of epilepsy after anti-neuronal antibody-positive autoimmune encephalitis (AIE). The clinical outcomes of patients with epilepsy after AIE were also explored. METHODS A total of 111 AIE patients were retrospectively evaluated. Post-AIE epilepsy (PAEE) was defined as at least one unprovoked seizure occurring six or more months after discharge from hospital. RESULTS The incidence of acute symptomatic seizures was 80.2% (89/111) in our AIE patients. Furthermore, of the 89 AIE patients with seizures, 29 (32.6%) presented with seizures as the initial symptom. Overall, 44 out of 111 AIE patients (39.6%) had unprovoked seizures after six months, meeting our definition of PAEE. The independent risk factors for PAEE incidence included an initial presentation with new-onset refractory status epilepticus (NORSE), delayed immunotherapy treatment, the complication of a lung infection during admission, the requirement for mechanical ventilation during hospitalization, parietal lesions observed in magnetic resonance imaging (MRI), and focal slow waves on electroencephalographic (EEG) monitoring. CONCLUSIONS Early initiation of immunotherapy and lung infection treatment may reduce the risk of conversion of symptomatic seizures to chronic epilepsy in the acute phase of AIE. In general, PAEE patients could have a good prognosis if treated properly and in a timely fashion.
Collapse
Affiliation(s)
- Shan-Shan Chen
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China
| | - Yan-Fang Zhang
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China
| | - Qing Di
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China
| | - Jing-Ping Shi
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China
| | - Ling-Ling Wang
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China
| | - Xing-Jian Lin
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China.
| | - Nian Yu
- Department of Neurology, The Nanjing Brain Hospital Affiliated Nanjing Medical University, 210029 Nanjing, China.
| |
Collapse
|
11
|
Wu H, Wang Y, Wei K, Qiao S, Liu L, Zhang R, Cao L, Wang S, Liu X. Clinical characteristics and elevated ProGRP and positive oligoclonal bands of 13 Chinese cases with anti-GABABR encephalitis. Int J Dev Neurosci 2021; 81:492-501. [PMID: 33973258 DOI: 10.1002/jdn.10121] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/20/2021] [Accepted: 04/30/2021] [Indexed: 01/21/2023] Open
Abstract
OBJECTIVE To improve the clinical understanding of anti-gamma-aminobutyric-acid B receptor encephalitis (anti-GABABR encephalitis) by analyzing 13 cases. METHODS We retrospectively studied demographic and clinical features including clinical symptoms, serum/cerebrospinal fluid (CSF) laboratory findings (including antibody test), brain magnetic resonance imaging (MRI), electroencephalogram (EEG), treatment plan, and treatment effect for 13 patients with a definitive diagnosis of anti-GABABR encephalitis. RESULTS Seven patients (53.8%, 7/13) were complicated with lung cancer. Epileptic seizures were the most common symptoms at onset in 11 patients (84.6%, 11/13). All patients had seizures in the course of the disease. Abnormalities in craniocerebral MRI examination, including hippocampus, occipital lobe, insular lobe, were found in six of nine tested patients, and EEG abnormalities were found in seven out of nine tested patients. Elevated pro-gastrin releasing peptide (ProGRP) levels were found in 70% of patients with a median value of 490.10 pg/ml; and CSF oligoclonal bands were positive for 4 of 10 tested cases. However, there were no significant differences in modified Rankin Scale (mRS) between the ProGRP or CSF oligoclonal band positive and negative groups at admission and follow-up (p > .05). The value between SCLC and non-SCLC subgroup was significantly different (p < .05). Ten patients received immunotherapy (three patients refused treatment). After immunotherapy, the frequency of seizures was significantly reduced. There was a significant difference in mRS between admission and after treatment (p < .05). The average survival time after onset was 27.7 months. CONCLUSIONS Epilepsy is the most common clinical manifestation of Anti-GABABR encephalitis. The prognosis of anti-GABABR encephalitis is poor. Section of anti-GABABR encephalitis patients have higher level of serum ProGRP and positive GSF oligoclonal bands. Elevated ProGRP or positive CSF oligoclonal bands with classic clinical features can potentially help to improve early recognition of anti-GABABR encephalitis.
Collapse
Affiliation(s)
- Huaikuan Wu
- Department of Interventional Radiology, Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Yuliang Wang
- Department of Neurology, Binzhou Medical University Hospital, Binzhou, China
| | - Kunkun Wei
- Department of Neurology, The Fourth People's Hospital of Jinan, Jinan, China
| | - Shan Qiao
- Department of Neurology, Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Lingling Liu
- Department of Neurology, Liaocheng People's Hospital, Liaocheng, China
| | - Ranran Zhang
- Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Institute of Epilepsy, Shandong University, Jinan, China
| | - Lili Cao
- Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Institute of Epilepsy, Shandong University, Jinan, China
| | - Shengjun Wang
- Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Institute of Epilepsy, Shandong University, Jinan, China
| | - Xuewu Liu
- Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Institute of Epilepsy, Shandong University, Jinan, China
| |
Collapse
|
12
|
Nissan E, Watad A, Cohen AD, Sharif K, Nissan J, Amital H, Shovman O, Bragazzi NL. Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph18083983. [PMID: 33920065 PMCID: PMC8068784 DOI: 10.3390/ijerph18083983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/04/2021] [Accepted: 04/06/2021] [Indexed: 11/16/2022]
Abstract
Polymyositis (PM) and dermatomyositis (DM) are autoimmune-mediated multisystemic myopathies, characterized mainly by proximal muscle weakness. A connection between epilepsy and PM/DM has not been reported previously. Our study aim is to evaluate this association. A case–control study was conducted, enrolling a total of 12,278 patients with 2085 cases (17.0%) and 10,193 subjects in the control group (83.0%). Student’s t-test was used to evaluate continuous variables, while the chi-square test was applied for the distribution of categorical variables. Log-rank test, Kaplan–Meier curves and multivariate Cox proportional hazards method were performed for the analysis regarding survival. Of the studied 2085 cases, 1475 subjects (70.7%) were diagnosed with DM, and 610 patients (29.3%) with PM. Participants enrolled as cases had a significantly higher rate of epilepsy (n = 48 [2.3%]) as compared to controls (n = 141 [1.4%], p < 0.0005). Using multivariable logistic regression analysis, PM was found only to be significantly associated with epilepsy (OR 2.2 [95%CI 1.36 to 3.55], p = 0.0014), whereas a non-significant positive trend was noted in DM (OR 1.51 [95%CI 0.99 to 2.30], p = 0.0547). Our data suggest that PM is associated with a higher rate of epilepsy compared to controls. Physicians should be aware of this comorbidity in patients with immune-mediated myopathies.
Collapse
Affiliation(s)
- Ella Nissan
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Abdulla Watad
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Arnon D. Cohen
- Chief Physician’s Office, Clalit Health Services, Tel Aviv 16250, Israel;
- Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8489325, Israel
| | - Kassem Sharif
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Johnatan Nissan
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
- Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer 5262000, Israel
| | - Howard Amital
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Ora Shovman
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Nicola Luigi Bragazzi
- Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, ON M3J 1P3, Canada
- Correspondence:
| |
Collapse
|
13
|
Abstract
PURPOSE OF REVIEW Neurologic complications in patients with cancer can significantly impact morbidity and mortality. Although these complications can be seen in patients without cancer as well, the purpose of this review is to highlight how the presentation, etiology, and management of delirium, seizures, cerebrovascular disease, and central nervous system infections may be different in patients with cancer. RECENT FINDINGS Some of the newer anticancer therapies are associated with neurologic complications. Delirium and seizures have been described in patients receiving chimeric antigen receptor (CAR) T-cell therapy and other immune effector cell therapies. Angiogenesis inhibitors can increase the risk of bleeding and clotting, including intracranial hemorrhage and stroke. The risk of opportunistic fungal infections, including aspergillosis, is elevated with the Bruton tyrosine kinase inhibitor ibrutinib. SUMMARY Providers should familiarize themselves with neurologic complications in patients with cancer because early diagnosis and intervention can improve outcomes. The differential diagnosis should be broad, including conventional causes as seen in patients who do not have cancer, with special consideration of etiologies specific to patients with cancer.
Collapse
|
14
|
Rada A, Birnbacher R, Gobbi C, Kurthen M, Ludolph A, Naumann M, Neirich U, von Oertzen TJ, Ransmayr G, Riepe M, Schimmel M, Schwartz O, Surges R, Bien CG. Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data. J Neurol 2020; 268:1059-1069. [PMID: 33025119 PMCID: PMC7914192 DOI: 10.1007/s00415-020-10250-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Revised: 09/25/2020] [Accepted: 09/28/2020] [Indexed: 02/06/2023]
Abstract
Background Clinicians have questioned whether any disorder involving seizures and neural antibodies should be called “(auto)immune epilepsy.” The concept of “acute symptomatic seizures” may be more applicable in cases with antibodies against neural cell surface antigens. We aimed at determining the probability of achieving seizure-freedom, the use of anti-seizure medication (ASM), and immunotherapy in patients with either constellation. As a potential pathophysiological correlate, we analyzed antibody titer courses. Methods Retrospective cohort study of 39 patients with seizures and neural antibodies, follow-up ≥ 3 years. Results Patients had surface antibodies against the N-methyl-d-aspartate receptor (NMDAR, n = 6), leucine-rich glioma inactivated protein 1 (LGI1, n = 11), contactin-associated protein-2 (CASPR2, n = 8), or antibodies against the intracellular antigens glutamic acid decarboxylase 65 kDa (GAD65, n = 13) or Ma2 (n = 1). Patients with surface antibodies reached first seizure-freedom (88% vs. 7%, P < 0.001) and terminal seizure-freedom (80% vs. 7%, P < 0.001) more frequently. The time to first and terminal seizure-freedom and the time to freedom from ASM were shorter in the surface antibody group (Kaplan–Meier curves: P < 0.0001 for first seizure-freedom; P < 0.0001 for terminal seizure-freedom; P = 0.0042 for terminal ASM-freedom). Maximum ASM defined daily doses were higher in the groups with intracellular antibodies. Seizure-freedom was achieved after additional immunotherapy, not always accompanied by increased ASM doses. Titers of surface antibodies but not intracellular antibodies decreased over time. Conclusion Seizures with surface antibodies should mostly be considered acute symptomatic and transient and not indicative of epilepsy. This has consequences for ASM prescription and social restrictions. Antibody titers correlate with clinical courses. Electronic supplementary material The online version of this article (10.1007/s00415-020-10250-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anna Rada
- Epilepsy Center Bethel, Krankenhaus Mara, Epilepsy Centre Bethel, Krankenhaus Mara, Maraweg 17-21, 33617, Bielefeld, Germany
| | - Robert Birnbacher
- Department of Pediatrics and Adolescent Medicine, Villach General Hospital, Villach, Austria
| | - Claudio Gobbi
- Department of Neurology, Neurocenter of Southern Switzerland (NSI), 6900, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI), 6900, Lugano, Switzerland
| | | | - Albert Ludolph
- Department of Neurology, University of Ulm, Ulm, Germany
| | - Markus Naumann
- Department of Neurology and Clinical Neurophysiology, University of Augsburg, Augsburg, Germany
| | - Ulrike Neirich
- Department of Pediatrics, Neurology, Stiftungskrankenhäuser Frankfurt Am Main, Clementine Kinderhospital, Frankfurt am Main, Germany
| | - Tim J von Oertzen
- Department of Neurology 1, Kepler University Hospital GmbH, Johannes Kepler University Linz, Linz, Austria
| | - Gerhard Ransmayr
- Department of Neurology 2, Kepler University Hospital GmbH, Johannes Kepler University Linz, Linz, Austria
| | - Matthias Riepe
- Division of Gerontopsychiatry, Ulm University, Günzburg, Germany
| | - Mareike Schimmel
- Department of Pediatrics, Section of Neuropediatrics, University of Augsburg, Augsburg, Germany
| | - Oliver Schwartz
- Department of Pediatric Neurology, Münster University Hospital, Münster, Germany
| | - Rainer Surges
- Department of Epileptology, University Hospital of Bonn, Bonn, Germany
| | - Christian G Bien
- Epilepsy Center Bethel, Krankenhaus Mara, Epilepsy Centre Bethel, Krankenhaus Mara, Maraweg 17-21, 33617, Bielefeld, Germany.
- Laboratory Krone, Bad Salzuflen, Germany.
| |
Collapse
|
15
|
Abstract
AbstractEpilepsy is a chronic neurological disorder that has an extensive impact on a patient’s life. Accumulating evidence has suggested that inflammation participates in the progression of spontaneous and recurrent seizures. Pro-convulsant incidences can stimulate immune cells, augment the release of pro-inflammatory cytokines, elicit neuronal excitation as well as blood-brain barrier (BBB) dysfunction, and finally trigger the generation or recurrence of seizures. Understanding the pathogenic roles of inflammatory mediators, including inflammatory cytokines, cells, and BBB, in epileptogenesis will be beneficial for the treatment of epilepsy. In this systematic review, we performed a literature search on the PubMed database using the following keywords: “epilepsy” or “seizures” or “epileptogenesis”, and “immunity” or “inflammation” or “neuroinflammation” or “damage-associated molecular patterns” or “cytokines” or “chemokines” or “adhesion molecules” or “microglia” or “astrocyte” or “blood-brain barrier”. We summarized the classic inflammatory mediators and their pathogenic effects in the pathogenesis of epilepsy, based on the most recent findings from both human and animal model studies.
Collapse
|
16
|
Barber E, Nugzar R, Finkelshtein V, Puzhevsky A, Levy T. Posterior reversible encephalopathy syndrome case report in an untreated, normotensive, ovarian cancer patient in the presence of paraneoplastic antibodies. BMC Neurol 2020; 20:330. [PMID: 32878599 PMCID: PMC7466806 DOI: 10.1186/s12883-020-01913-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 08/27/2020] [Indexed: 01/08/2023] Open
Abstract
Background Posterior reversible encephalopathy syndrome (PRES) is a rare neurological condition with many associated risk factors. The presentation varies and consists of seizures, impaired visual acuity or visual field deficits, disorders of consciousness, headaches, confusion and focal neurological deficits. The diagnosis relies on clinical presentation and MRI findings. Treatment and prognosis are related to the underlying etiology. Case presentation We present a 58-year-old woman with ovarian cancer who developed symptoms and radiologic signs of PRES with no apparent trigger other than a sudden increase in blood pressure for the first time in her life and before any treatment has begun. Antibodies to collapsin response-mediator protein-5 (CRMP-5), a malignancy related paraneoplastic protein, were identified in her CSF. Conclusions We present a novel and intriguing association between PRES and antibodies against CRMP-5 which may highlight a new etiology for this condition.
Collapse
Affiliation(s)
- Elad Barber
- Division of Gynecologic Oncology, Wolfson Medical Center, Holon, Israel. .,Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, P.O. Box 5, 58100, Holon, Israel. .,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | - Rijini Nugzar
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Anesthesia, Wolfson Medical Center, Holon, Israel
| | - Vitaly Finkelshtein
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Neurology, Wolfson Medical Center, Holon, Israel
| | - Alexander Puzhevsky
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Diagnostic Radiology, Wolfson Medical Center, Holon, Israel
| | - Tally Levy
- Division of Gynecologic Oncology, Wolfson Medical Center, Holon, Israel.,Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, P.O. Box 5, 58100, Holon, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
17
|
Zhu F, Shan W, Lv R, Li Z, Wang Q. Clinical Characteristics of Anti-GABA-B Receptor Encephalitis. Front Neurol 2020; 11:403. [PMID: 32508739 PMCID: PMC7253677 DOI: 10.3389/fneur.2020.00403] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Accepted: 04/17/2020] [Indexed: 01/06/2023] Open
Abstract
Objective: Anti-GABA-B (gamma aminobutyric acid-B) receptor encephalitis is an autoimmune disease mediated by GABA-B-related antibodies. To fully understand the disease, we collected clinical data from patients with GABA-B receptor encephalitis and conducted an analysis to draw conclusions. Methods: All patients with GABA-B receptor encephalitis from the Neurology Department of Beijing Tiantan Hospital, affiliated with Capital Medical University, from August 2015 to September 2019 were accepted as study subjects. The clinical data of the patients were analyzed retrospectively and included the general demographic characteristics, clinical manifestations, and auxiliary examinations, including laboratory results, electroencephalograms (EEGs), brain magnetic resonance imaging (MRI), and positron emission tomography (PET-CT) results, as well as treatments. Results: From August 2015 to September 2019, 14 cases of anti-GABA-B receptor encephalitis were diagnosed. Among these patients, middle-aged and elderly men were the main demographic, with an average age of 52 years; moreover, the onset of the disease was relatively sudden, and the time from onset to diagnosis was ~1 month. The main clinical symptoms were frequent epileptic seizures, cognitive dysfunction, and mental behavioral disorders. In seven (50%) patients, the leukocyte in cerebrospinal fluid (CSF) were increased. Five (36%) patients had elevated cerebrospinal fluid protein. In most patients, the oligoclonal bands (83%) of CSF were positive, and 24 h IgG levels (92%) were increased. Anti-Hu or anti-Yo antibodies were positive in two (14%) patients. Tumor markers in 10 (71%) patients indicated that neuron-specific enolase, gastrin-releasing precursor, non-small cell lung cancer-related antigen, or carcinoembryonic antigen levels were increased. EEG results often indicated slow waves, sharp waves, or spike waves in temporal areas. Brain MRI always showed high T2 signals in the medial temporal lobe, hippocampus, and amygdala and swelling in the medial temporal lobe and hippocampus. PET-CT scans almost showed abnormal metabolism in the hippocampus and temporal lobe. Three (21%) patients who underwent systemic PET-CT showed hypermetabolism in pulmonary parenchymal nodules and enlargement of mediastinal lymph nodes. All patients underwent high-dose hormone therapy or immunoglobulin immunotherapy. After treatment, the symptoms of epilepsy, cognitive disorders, and mental behavioral disorders improved to varying degrees. However, one patient died of lung cancer. Conclusion: Anti-GABA-B receptor encephalitis mainly occurred in middle-aged and elderly men, and the disease onset was relatively sudden. Before disease onset, some patients experienced fever and non-specific respiratory symptoms, which mainly manifested as frequent epileptic seizures, cognitive dysfunction, and abnormal mental behavior. MRI and PET-CT revealed abnormal signals and local metabolism, respectively, in the temporal lobe. Moreover, the disease has a close relationship with lung cancer, which requires long-term follow-up observation.
Collapse
Affiliation(s)
- Fei Zhu
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China
| | - Wei Shan
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Beijing Institute for Brain Disorders, Beijing, China
| | - Ruijuan Lv
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China
| | - Zhimei Li
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China
| | - Qun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Beijing Institute for Brain Disorders, Beijing, China
| |
Collapse
|
18
|
Immune-mediated epilepsy with GAD65 antibodies. J Neuroimmunol 2020; 341:577189. [PMID: 32087461 DOI: 10.1016/j.jneuroim.2020.577189] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2020] [Revised: 02/11/2020] [Accepted: 02/11/2020] [Indexed: 12/18/2022]
Abstract
Anti-GAD65 antibodies have been identified in both acute/subacute seizures (limbic encephalitis and extralimbic encephalitis) and chronic isolated epilepsy. The evidence of high serum titers and intrathecal synthesis play a fundamental role in diagnosis but poorly correlate with disease severity or response to therapies. It remains controversial whether anti-GAD65 Abs are the pathogenic entity or only serve as a surrogate marker for autoimmune disorders mediated by cytotoxic T cells. Unlike other immune-mediated epilepsy, although multiple combinations of therapeutics are used, the efficacy and prognosis of patients with GAD65-epilepsy patients are poor. Besides, GAD65-epilepsy is more prone to relapse and potentially evolve into a more widespread CNS inflammatory disorder. This article reviews the recent advances of GAD65-epilepsy, focusing on the diagnosis, epidemiology, pathophysiology, clinical features, and treatment, to better promote the recognition and provide proper therapy for this condition.
Collapse
|
19
|
Zhang X, Lang Y, Sun L, Zhang W, Lin W, Cui L. Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China. BMC Neurol 2020; 20:1. [PMID: 31900128 PMCID: PMC6941279 DOI: 10.1186/s12883-019-1585-y] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 12/22/2019] [Indexed: 12/20/2022] Open
Abstract
Objective To investigate the clinical characteristics and prognosis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis. Methods This retrospective study enrolled nineteen patients with anti-GABA-B receptor encephalitis. Clinical manifestations, radiological and electroencephalogram features, treatment and outcomes were collected and analyzed. The neurological function was evaluated according to the modified Rankin Scale (mRS). Results There were eleven patients in the favorable-prognosis group (mRS ≤ 2) and eight patients in the poor-prognosis group (mRS > 2). In the favorable-prognosis group, clinical symptoms included memory deterioration (n = 10; 90.9%), epileptic seizures (n = 9; 81.8%), psychiatric disorders (n = 9; 81.8%), and conscious disturbance (n = 5; 45.5%); magnetic resonance imaging (MRI) indicated an involvement of the limbic system in three (27.3%) cases in this group. Lung cancer was detected in one patient (9.1%). After an average follow-up period of 11.7 months, four (36.4%) patients were cured, and seven (63.6%) patients showed significant improvements. In the poor-prognosis group, all patients presented with memory deterioration, epileptic seizures, psychiatric disorders, and conscious disturbance; five (62.5%) patients had convulsive status epilepticus, and five (62.5%) patients developed respiratory failure; MRI indicated an involvement of the limbic system in seven (87.5%) cases. Malignant tumors were detected in five (62.5%) patients. After an average follow-up period of 14.8 months, seven (87.5%) patients died and one (12.5%) patient remained dependent in daily life. Conclusions The clinical manifestations of anti-GABA-B receptor encephalitis include epileptic seizures, cognitive impairment and psychiatric disorders. Patients with convulsive status epilepticus or respiratory failure have poor outcomes. In anti-GABA-B receptor encephalitis, limbic system involvement is associated with a poor prognosis in and radiological examinations can reflect disease progression. Early diagnosis and appropriate treatment should be highlighted.
Collapse
Affiliation(s)
- Xinyue Zhang
- Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China
| | - Yue Lang
- Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China
| | - Lichao Sun
- Department of Emergency, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China
| | - Weiguanliu Zhang
- Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China
| | - Weihong Lin
- Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China
| | - Li Cui
- Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, China.
| |
Collapse
|
20
|
Zeng W, Cao L, Zheng J, Yu L. Clinical characteristics and long-term follow-up of seven cases of anti-GABABR encephalitis in patients of Han Chinese descent. Neurol Sci 2019; 41:373-378. [PMID: 31659584 PMCID: PMC7005084 DOI: 10.1007/s10072-019-04095-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 09/30/2019] [Indexed: 12/12/2022]
Abstract
Objective To improve the diagnosis and treatment of anti-GABAB receptor (anti-GABABR) encephalitis and prevent misdiagnosis or non-diagnosis. Methods We retrospectively examined the chief clinical manifestations, auxiliary examination results, treatment strategies, treatment efficacy, and long-term follow-up results of seven consecutive patients with anti-GABABR encephalitis. Results Epileptic seizures were the first symptom in 100% of the patients; 85.7% had memory deficit in the hospital, 42.8% had residual symptoms of cognitive impairment at discharge, and 28.6% had cognitive impairment at the end of follow-up; 71.4% of the patients had psychosis in the hospital, 57.1% had residual symptoms of psychosis at discharge, and 14.3% still had psychosis at the end of follow-up. However, the clinical symptoms (psychiatric disorders, cognitive decline) and signs (consciousness disturbance) at onset and after follow-up were not significantly different (P > 0.05). In 71.4% of the patients, anti-GABABR antibody serum levels were higher than those in the cerebrospinal fluid (especially in patients with lung cancer). Magnetic resonance imaging in 71.4% of patients indicated that the marginal lobe demonstrated encephalitis lesions. The average modified Rankin Scale score (2.0 ± 2.31) at follow-up was significantly better than that (3.86 ± 0.90) at the time of admission (P < 0.05). Conclusion The clinical characteristics of anti-GABABR encephalitis were refractory epilepsy, psychiatric disorders, and cognitive impairment. Multiple antiepileptic drugs are crucial for the treatment of intractable epilepsy. Clinicians should eliminate the possibility of small-cell lung cancer in patients with high anti-GABABR antibody levels. Early active immunotherapy is effective, and the long-term prognosis is good for patients without tumors.
Collapse
Affiliation(s)
- Wei Zeng
- Department of Neurology, Liuzhou People's Hospital, Wenchang Road, Chengzhong District, Liuzhou City, 545000, China
| | - Liming Cao
- Department of Neurology, The 3rd Affiliated Hospital of Shenzhen University, 47 Friendship Road, Luohu District, Shenzhen City, 518000, China.
| | - Jinou Zheng
- Department of Neurology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Qingxiu District, Nanning City, 530021, China
| | - Lu Yu
- Department of Neurology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Qingxiu District, Nanning City, 530021, China
| |
Collapse
|
21
|
Hasegawa D, Ohnishi Y, Koyama E, Matsunaga S, Ohtani S, Nakanishi A, Shiga T, Chambers JK, Uchida K, Yokoi N, Fukata Y, Fukata M. Deleted in colorectal cancer (netrin-1 receptor) antibodies and limbic encephalitis in a cat with hippocampal necrosis. J Vet Intern Med 2019; 33:1440-1445. [PMID: 30942925 PMCID: PMC6524083 DOI: 10.1111/jvim.15492] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 03/19/2019] [Indexed: 12/01/2022] Open
Abstract
A 7‐year‐old neutered female domestic shorthaired cat born in Poland and then moved to Japan presented to the local clinic with recent onset of convulsive cluster seizures and status epilepticus. Magnetic resonance imaging revealed bilateral swelling of the hippocampus with T2 hyperintensity and contrast enhancing image, suggesting hippocampal necrosis. The cat completely recovered after treatment with antiepileptic drugs (AED) and administration of prednisolone (1 mg/kg PO q24h for 4 days and tapered). However, cluster seizures reoccurred and developed into status epilepticus despite increasing doses of AED. Although the convulsions were resolved by other AEDs, stupor and renal failure developed, and the cat was euthanized. Pathological findings were consistent with hippocampal necrosis. Immunological analysis for leucine‐rich glioma inactivated 1 (LGI1) autoantibodies was negative, but antibodies against DCC (deleted in colorectal carcinoma) known as netrin‐1 receptor were found. This report describes a case of feline autoimmune limbic encephalitis and hippocampal necrosis that were presumably associated with DCC autoantibodies.
Collapse
Affiliation(s)
- Daisuke Hasegawa
- Department of Veterinary Clinical Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan
| | - Yumi Ohnishi
- Companion Animal Medical Imaging Center, Tokyo, Japan
| | - Eiji Koyama
- Companion Animal Medical Imaging Center, Tokyo, Japan.,Sendai General Animal Hospital, Miyagi, Japan
| | | | | | | | - Takanori Shiga
- Laboratory of Veterinary Pathology, The University of Tokyo, Tokyo, Japan
| | - James K Chambers
- Laboratory of Veterinary Pathology, The University of Tokyo, Tokyo, Japan
| | - Kazuyuki Uchida
- Laboratory of Veterinary Pathology, The University of Tokyo, Tokyo, Japan
| | - Norihiko Yokoi
- Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Science, Aichi, Japan
| | - Yuko Fukata
- Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Science, Aichi, Japan
| | - Masaki Fukata
- Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Science, Aichi, Japan
| |
Collapse
|
22
|
Shen K, Xu Y, Guan H, Zhong W, Chen M, Zhao J, Li L, Wang M. Paraneoplastic limbic encephalitis associated with lung cancer. Sci Rep 2018; 8:6792. [PMID: 29717222 PMCID: PMC5931551 DOI: 10.1038/s41598-018-25294-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 03/28/2018] [Indexed: 12/11/2022] Open
Abstract
Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in lung cancer patients. We retrospectively investigated the clinical characteristics, treatment responses, and prognoses in 16 PLE patients who were subsequently diagnosed with lung cancer. Fifteen patients initially presented with disturbance of consciousness, 13 with disorientation, and 12 with seizures. Thirteen patients had autoantibodies, including eight with gamma aminobutyric acid B receptor (GABABR) antibodies and eight with Hu antibodies. PET-CT revealed lung neoplasms in 13 patients, nine of whom exhibited abnormal metabolic activity in the temporal lobe and hippocampus. Fifteen cases were confirmed as limited-stage small cell lung cancer and one as stage IV large cell neuroendocrine carcinoma. Eleven patients received immunomodulatory therapy, and four showed neurological improvement, who all had antibodies against GABABR. Fifteen patients received chemotherapy, of which 14 maintained or improved their PLE status. The overall cancer response rate was 75%, and two-year overall survival was 74.7%. Our results suggest patients with GABAB encephalitis might respond better to immunotherapy than the classical PLE patients with anti-Hu antibodies. Anti-cancer treatment could further improve neurological symptoms. Lung cancer patients with PLE, especially those in limited stage, might have better outcome due to earlier diagnosis and prompt anti-cancer treatment.
Collapse
Affiliation(s)
- Kaini Shen
- Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Yan Xu
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Hongzhi Guan
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Wei Zhong
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Minjiang Chen
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Jing Zhao
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Longyun Li
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Mengzhao Wang
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
| |
Collapse
|
23
|
Tecellioglu M, Kamisli O, Kamisli S, Yucel FE, Ozcan C. Neurological autoantibodies in drug-resistant epilepsy of unknown cause. Ir J Med Sci 2018. [PMID: 29524102 DOI: 10.1007/s11845-018-1777-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Autoimmune epilepsy is a rarely diagnosed condition. Recognition of the underlying autoimmune condition is important, as these patients can be resistant to antiepileptic drugs. AIMS To determine the autoimmune and oncological antibodies in adult drug-resistant epilepsy of unknown cause and identify the clinical, radiological, and EEG findings associated with these antibodies according to data in the literature. METHODS Eighty-two patients with drug-resistant epilepsy of unknown cause were prospectively identified. Clinical features were recorded. The levels of anti-voltage-gated potassium channel complex (anti-VGKCc), anti-thyroid peroxidase (anti-TPO), anti-nuclear antibody (ANA), anti-glutamic acid decarboxylase (anti-GAD), anti-phospholipid IgG and IgM, anti-cardiolipin IgG and IgM, and onconeural antibodies were determined. RESULTS Serum antibody positivity suggesting the potential role of autoimmunity in the aetiology was present in 17 patients with resistant epilepsy (22.0%). Multiple antibodies were found in two patients (2.6%). One of these patients (1.3%) had anti-VGKCc and ANA, whereas another (1.3%) had anti-VGKCc and anti-TPO. A single antibody was present in 15 patients (19.5%). Of the 77 patients finally included in the study, 4 had anti-TPO (5.2%), 1 had anti-GAD (1.3%), 4 had anti-VGKCc (5.2%) 8 had ANA (10.3%), and 2 had onconeural antibodies (2.6%) (1 patient had anti-Yo and 1 had anti-MA2/TA). The other antibodies investigated were not detected. EEG abnormality (focal), focal seizure incidence, and frequent seizures were more common in antibody-positive patients. CONCLUSION Autoimmune factors may be aetiologically relevant in patients with drug-resistant epilepsy of unknown cause, especially if focal seizures are present together with focal EEG abnormality and frequent seizures.
Collapse
Affiliation(s)
- Mehmet Tecellioglu
- Department of Neurology, Inonu University, School of Medicine, Malatya, Turkey.
| | - Ozden Kamisli
- Department of Neurology, Inonu University, School of Medicine, Malatya, Turkey
| | - Suat Kamisli
- Department of Neurology, Inonu University, School of Medicine, Malatya, Turkey
| | - Fatma Ebru Yucel
- Department of Neurology, Malatya State Hospital, Malatya, Turkey
| | - Cemal Ozcan
- Department of Neurology, Inonu University, School of Medicine, Malatya, Turkey
| |
Collapse
|
24
|
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav 2018; 80:331-336. [PMID: 29433947 DOI: 10.1016/j.yebeh.2018.01.021] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 01/16/2018] [Accepted: 01/17/2018] [Indexed: 01/21/2023]
Abstract
Glutamic acid decarboxylase (GAD) antibody-associated encephalitis causes both acute seizures and chronic epilepsy with predominantly temporal lobe onset. This condition is challenging in diagnosis and management, and the incidence of GAD antibody (Ab)-related epilepsy could be much higher than commonly believed. Imaging and CSF evidence of inflammation along with typical clinical presentations, such as adult onset temporal lobe epilepsy (TLE) with unexplained etiology, should prompt testing for the diagnostic antibodies. High serum GAD Ab titer (≥2000U/mL or ≥20nmol/L) and evidence of intrathecal anti-GAD Ab synthesis support the diagnosis. Unlike other immune-mediated epilepsies, antiglutamic acid decarboxylase 65 (GAD65) antibody-mediated epilepsy is often poorly responsive to antiepileptic drugs (AEDs) and only moderately responsive to immune therapy with steroids, intravenous immunoglobulin (IVIG), or plasma exchange (PLEX). Long-term treatment with more aggressive immunosuppressants such as rituximab (RTX) and/or cyclophosphamide is often necessary and may be more effective than current immunosuppressive approaches. The aim of this review is to review the physiology, pathology, clinical presentation, related ancillary tests, and management of GAD Ab-associated autoimmune epilepsy by searching the keywords and to promote the recognition and the initiation of proper therapy for this condition.
Collapse
|
25
|
Hemiataxia: A Novel Presentation of Anti-NMDA Receptor Antibody Mediated Encephalitis in an Adolescent. Case Rep Psychiatry 2017; 2017:1310465. [PMID: 29333310 PMCID: PMC5733199 DOI: 10.1155/2017/1310465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 08/21/2017] [Accepted: 08/30/2017] [Indexed: 12/17/2022] Open
Abstract
Anti-NMDA receptor antibody associated encephalitis as a cause of new-onset neuropsychiatric manifestations in children and adults can represent a significant diagnostic challenge for clinicians. Clinical signs often include encephalopathy, new-onset psychosis, and movement phenomenon. Although orofacial dyskinesias were initially identified as a characteristic movement phenomenon in this type of encephalitis, an expanded range of abnormalities has recently been reported, including isolated ataxia. We report a case of isolated hemiataxia in a young adult with mild initial psychiatric manifestations. A personal and family history of preceding neuropsychiatric symptoms produced diagnostic confusion and resulted in a significant diagnostic and therapeutic delay. Our case confirms the unilateral movement manifestations that have been emphasized in recent reports. Additionally, it confirms the need for involvement of neurologic as well as psychiatric services in the evaluation of such cases and emphasizes the importance of the neurologic examination in presentations with an initial psychiatric predominance.
Collapse
|
26
|
Kerr WT, Janio EA, Braesch CT, Le JM, Hori JM, Patel AB, Gallardo NL, Bauirjan J, D'Ambrosio SR, Chau AM, Hwang ES, Davis EC, Buchard A, Torres-Barba D, Al Banna M, Barritt SE, Cho AY, Engel J, Cohen MS, Stern JM. Identifying psychogenic seizures through comorbidities and medication history. Epilepsia 2017; 58:1852-1860. [PMID: 28895657 DOI: 10.1111/epi.13888] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/08/2017] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Low-cost evidence-based tools are needed to facilitate the early identification of patients with possible psychogenic nonepileptic seizures (PNES). Prior to accurate diagnosis, patients with PNES do not receive interventions that address the cause of their seizures and therefore incur high medical costs and disability due to an uncontrolled seizure disorder. Both seizures and comorbidities may contribute to this high cost. METHODS Based on data from 1,365 adult patients with video-electroencephalography-confirmed diagnoses from a single center, we used logistic and Poisson regression to compare the total number of comorbidities, number of medications, and presence of specific comorbidities in five mutually exclusive groups of diagnoses: epileptic seizures (ES) only, PNES only, mixed PNES and ES, physiologic nonepileptic seizurelike events, and inconclusive monitoring. To determine the diagnostic utility of comorbid diagnoses and medication history to differentiate PNES only from ES only, we used multivariate logistic regression, controlling for sex and age, trained using a retrospective database and validated using a prospective database. RESULTS Our model differentiated PNES only from ES only with a prospective accuracy of 78% (95% confidence interval =72-84%) and area under the curve of 79%. With a few exceptions, the number of comorbidities and medications was more predictive than a specific comorbidity. Comorbidities associated with PNES were asthma, chronic pain, and migraines (p < 0.01). Comorbidities associated with ES were diabetes mellitus and nonmetastatic neoplasm (p < 0.01). The population-level analysis suggested that patients with mixed PNES and ES may be a population distinct from patients with either condition alone. SIGNIFICANCE An accurate patient-reported medical history and medication history can be useful when screening for possible PNES. Our prospectively validated and objective score may assist in the interpretation of the medication and medical history in the context of the seizure description and history.
Collapse
Affiliation(s)
- Wesley T Kerr
- Department of Internal Medicine, Eisenhower Medical Center, Rancho Mirage, California, U.S.A.,Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.,Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Emily A Janio
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Chelsea T Braesch
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Justine M Le
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Jessica M Hori
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Akash B Patel
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Norma L Gallardo
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Janar Bauirjan
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Shannon R D'Ambrosio
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Andrea M Chau
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Eric S Hwang
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Emily C Davis
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Albert Buchard
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - David Torres-Barba
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Mona Al Banna
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Sarah E Barritt
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Andrew Y Cho
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Jerome Engel
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A.,Departments of Neurology and Neurobiology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.,Brain Research Institute, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - Mark S Cohen
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, U.S.A.,Departments of Neurology and Neurobiology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.,Departments of Radiology, Psychology, Biomedical Physics, and Bioengineering, University of California, Los Angeles, Los Angeles, California, U.S.A.,California NanoSystems Institute, University of California, Los Angeles, Los Angeles, California, U.S.A
| | - John M Stern
- Departments of Neurology and Neurobiology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A
| |
Collapse
|
27
|
Tsunoda Y, Kiwamoto T, Homma S, Yabuuchi Y, Kitazawa H, Shiozawa T, Nakazawa K, Hosaka T, Ishii K, Ishii A, Tamaoka A, Hizawa N. Paraneoplastic limbic encephalitis with late-onset magnetic resonance imaging findings: A case report. Mol Clin Oncol 2017; 7:259-262. [PMID: 28781798 DOI: 10.3892/mco.2017.1311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 04/11/2017] [Indexed: 11/05/2022] Open
Abstract
Paraneoplastic limbic encephalitis (PLE), a paraneoplastic neurological syndrome (PNS), is a rare nervous system disorder that results from the indirect effects of tumors and is commonly associated with small-cell lung cancer (SCLC). Previous studies have reported that magnetic resonance imaging (MRI) may be useful for diagnosing LE. Temporal lobe abnormalities are observed using T2-weighted and fluid-attenuated inversion recovery sequences; however, such abnormalities are detected in only 60% of patients with PLE. The present study describes a case of PLE associated with SCLC, in which LE was observed using MRI 26 days after the first convulsive seizure. Although the serum and cerebrospinal fluid analyses for onconeural antibodies were negative, the findings of this case indicate that PLE should be considered in the differential diagnosis, and that repeated brain MRI may be more helpful for diagnosis, as the brain MRI findings may be normal during the early stages of PLE.
Collapse
Affiliation(s)
- Yoshiya Tsunoda
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Takumi Kiwamoto
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Shinsuke Homma
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Yuuki Yabuuchi
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Haruna Kitazawa
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Toshihiro Shiozawa
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Kensuke Nakazawa
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Takashi Hosaka
- Department of Neurological Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Kazuhiro Ishii
- Department of Neurological Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Akiko Ishii
- Department of Neurological Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Akira Tamaoka
- Department of Neurological Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Nobuyuki Hizawa
- Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| |
Collapse
|
28
|
Scratching the Surface in Autoimmune Epilepsy: It is the Time to Dig Deeper, But How? Epilepsy Curr 2017; 17:225-226. [PMID: 29225526 DOI: 10.5698/1535-7597.17.4.225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|